Pacific 8 Ventures

BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.

Fauna Bio is developing new ways to treat human diseases, such as heart disease and neurodegenerative disease, by adopting mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists who have intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bio leverages data from hundreds of species in order to help develop pre-clinical and early clinical testing for new therapeutics targeting human diseases.

BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.

We are reinventing the claims process in private health insurance (PHI). Existing claims processes suffer from significant friction in the user journey and a lack of cost control for insurers. We eliminate the friction in this process while putting effective cost controls in place. Our solution is to provide insurers with co-branded debit cards distributed to their members. Each member can use their card at any health-related facility in the world - eliminating out-of-pocket expenses entirely. Think of corporate spend management providers like Payhawk, only for international and domestic private health insurers. So, the advantages are obvious: we help insurers to provide a 10x better user experience and to achieve substantial cost savings by providing structured data, offering real-time visibility on claims costs, minimizing fraudulent claims, and implementing a reward/cashback program to steer user behavior.

Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth Biosciences aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, and Cas14, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in South San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng Capital and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber. Mammoth has also been working on developing a rapid COVID-19 test.

Fauna Bio is developing new ways to treat human diseases, such as heart disease and neurodegenerative disease, by adopting mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists who have intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bio leverages data from hundreds of species in order to help develop pre-clinical and early clinical testing for new therapeutics targeting human diseases.

Bunkerhill Health is a group of academic institutions that together develop, test, and deploy AI algorithms in accordance with a set of processes.

Hint Health powers tomorrow's healthcare providers by giving them the tools they need to operate and administer their own plans, and by doing so compete directly with insurance-based models. Based in San Francisco and backed by top investors, Hint’s mission is to fix the broken healthcare system by fundamentally restructuring the way that care is delivered. Hint was co-founded in late 2013 by Stanford GSB alum Zak Holdsworth and CTO Graham Melcher. Their annual conference Hint Summit (summit.hint.com) brings together pioneering physicians, industry leaders, technology experts, and policy advocates who are at the forefront of healthcare reform in the US, to accelerate direct care and make it the new standard.

BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a liquid biopsy for infectious diseases. The Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.

Multiply Labs manufactures personalized pharmaceutical capsules that are tailor-made to the unique needs of each patient. Multiply Labs’ product is enabled by the combination of pharmaceutical science with robotics technology. The company has built and operates a unique robotic pharmaceutical manufacturing facility. Multiply Labs is the first company ever to bring to the market 3D printed capsules.

Wellthie is helping to modernize the insurance shopping experience, offering the first and only national small group benefits marketplace designed to help brokers optimize small group sales and carriers maximize product distribution. Wellthie’s enterprise-ready SaaS platform is available to carriers and brokers nationwide. Visit wellthie.com to learn more.

Quantified Care (QC) is a dveloper of a multimedia software platform for chronic care and post-discharge management with tools for patients and clinical management teams. Patients on the platform receive personalized updates and feedback based on symptoms, medication, and vitals data collected through regular check-ins delivered through the patient’s preferred mode of communication (mobile app, Alexa, text, phone call, or web portal). Data is captured manually or passively from connected devices and wearables. While patients receive support, clinical teams have access to analytics stratifying patients into high, medium, and low risk tiers based on QC’s clinical intelligence engine. Alerts trigger key clinical resources to take action while a secure communication layer facilitates remote patient engagement.

Labdoor is a testing lab that publicly verifies the quality of consumer products, starting with supplements. On Labdoor.com, consumers can find scientific product reviews and shop for hundreds of quality-tested supplements all in one place. They also offer a "Labdoor Certified" program to companies who submit every lot of their products to us for quality control testing. From their chemistry lab in South San Francisco, Labdoor analyzes the purity and potency of popular products to find out which ones have what they claim and if they have any harmful ingredients or contaminants. Then, they grade and rank those products, write reports, and publish that information for free, so consumers can confidently buy the best supplements for their needs.

Cohero Health offers a proprietary connected health platform for those with respiratory illness. Its sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers. The company offers a suite of tools and technology comprises form flexible inhaler sensors, mobile spirometers, to track real-time adherence and lung function, and a mobile application accessible on iPhone, iWatch, and Android. Cohero Health was founded in 2013 and is headquartered in New York.

Hint Health powers tomorrow's healthcare providers by giving them the tools they need to operate and administer their own plans, and by doing so compete directly with insurance-based models. Based in San Francisco and backed by top investors, Hint’s mission is to fix the broken healthcare system by fundamentally restructuring the way that care is delivered. Hint was co-founded in late 2013 by Stanford GSB alum Zak Holdsworth and CTO Graham Melcher. Their annual conference Hint Summit (summit.hint.com) brings together pioneering physicians, industry leaders, technology experts, and policy advocates who are at the forefront of healthcare reform in the US, to accelerate direct care and make it the new standard.